Advertisement

Treating Disease

  • University College NHS Foundation Trust and University College London

Abstract

Radionuclide therapy is one of the pillars of Nuclear Medicine. The radionuclide therapy programme at the Institute of Nuclear Medicine started with the use of radioiodine (I-131) for treatment of the benign overactive thyroid syndromes (Grave’s disease, autonomy, etc) expressed by increased thyroid hormone output - thyrotoxicosis, followed by the use of I-131 to treat malignant thyroid cancer. The management and treatment of thyrotoxicosis and of thyroid cancer was jointly carried out with the departments of Endocrinology and Radiotherapy, respectively. The treatment of these two entities comprised the bulk of the work, and remain so to date. Treating benign thyroid disease did not require any major change in practice, as patients were treated in the department of Nuclear Medicine on an outpatient basis. However, for thyroid cancer patients, designated rooms had to be identified.

Keywords

Thyroid Cancer Metabolic Tumour Volume Radionuclide Therapy Thyroid Cancer Patient Benign Thyroid Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, Ell PJ. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003 Jun; 15(4):193–8.CrossRefGoogle Scholar
  2. 2.
    Solanki KK, Bomanji JB, Waddington WA, Ell PJ; Thyroid blocking policy-revisited. UK Administration of Radioactive Substances Advisory Committee. Nucl Med Commun. 2004 Nov; 25(11):1071–6. No abstract available.PubMedCrossRefGoogle Scholar
  3. 3.
    Sawyer EJ, Cassoni AM, Waddington W, Bomanji JB, Briggs TW. Rhenium-186 HEDP as a boost to external beam irradiation in osteosarcoma. Br J Radiol. 1999; 72(864):1225–9.PubMedGoogle Scholar
  4. 4.
    Syed R, Bomanji J, Nagabhushan N, Kayani I, Groves A, Waddington W, Cassoni A, Ell PJ. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma. J Nucl Med. 2006 Dec; 47(12):1927–35.PubMedGoogle Scholar
  5. 5.
    Gains JE, Bomanji JB, Fersht NL, Sullivan T, D’Souza D, Sullivan KP, Aldridge M, Waddington W, Gaze MN. 177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma. J Nucl Med. 2011 Jul; 52(7):1041–7. Epub 2011 Jun 16.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • University College NHS Foundation Trust and University College London

There are no affiliations available

Personalised recommendations